COMMUNIQUÉS West-GlobeNewswire
-
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast
23/10/2025 -
Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)
23/10/2025 -
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
23/10/2025 -
Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting
23/10/2025 -
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
23/10/2025 -
Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025
23/10/2025 -
Tango Therapeutics Announces $225 Million Financing
23/10/2025 -
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
23/10/2025 -
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025 -
TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate
23/10/2025 -
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
23/10/2025 -
Conavi Medical to Highlight Novasight Hybrid™ Imaging at TCT 2025
23/10/2025 -
Redhook Brewing Launches Redhook 81, Celebrating Pacific Northwest Roots and the Spirit of Hard Work
23/10/2025 -
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
23/10/2025 -
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025 -
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
23/10/2025 -
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
23/10/2025 -
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
23/10/2025 -
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
23/10/2025
Pages